Payment overview · 2025
General Payments
$567.32
31 reported records · 9 companies
Healthcare provider profile · identity verified
Frances Leone Dilley, MD
Allopathic & Osteopathic Physicians|Family Medicine · MELBOURNE, FL · NPI 1508816950
Verified facts
What the public records show
CMS Open Payments records show Frances Leone Dilley, MD received $567.32 in general payments during 2025 across 31 reported records.
Exact Sciences Corporation accounted for 33.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $189.63 | 33.4% | 10 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $171.90 | 30.3% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.44 | 10.3% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.20 | 8.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.91 | 4.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.60 | 3.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.26 | 3.6% | 1 | 2025 |
| PhotoniCare Inc | Unresolved — no canonical attribution shown | $19.13 | 3.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.25 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $567.32 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $171.90 | 12 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $100.84 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $88.79 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $58.44 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $47.20 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| OtoSight Middle Ear Scope Normalized: otosight middle ear scope |
Device | PhotoniCare Inc | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 226 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 154 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 58 |
| Losartan Potassium | Losartan Potassium | 153 | 57 |
| Omeprazole | Omeprazole | 146 | 57 |
| Lisinopril | Lisinopril | 128 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 39 |
| Alprazolam | Alprazolam | 98 | 30 |
| Gabapentin | Gabapentin | 90 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 31 |
| Trazodone Hcl | Trazodone Hcl | 79 | 26 |
| Lorazepam | Lorazepam | 73 | 17 |
| Metformin Hcl | Metformin Hcl | 72 | 21 |
| Clonazepam | Clonazepam | 66 | suppressed |
| Mounjaro | Tirzepatide | 60 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 23 |
| Meloxicam | Meloxicam | 56 | 22 |
| Bupropion Xl | Bupropion Hcl | 55 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 20 |
| Prednisone | Prednisone | 50 | 37 |
| Sertraline Hcl | Sertraline Hcl | 48 | 15 |
| Simvastatin | Simvastatin | 48 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 18 |
| Methylprednisolone | Methylprednisolone | 45 | 32 |
| Trulicity | Dulaglutide | 43 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 29 |
| Furosemide | Furosemide | 35 | 15 |
| Montelukast Sodium | Montelukast Sodium | 35 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 13 |
| Potassium Chloride | Potassium Chloride | 33 | 12 |
| Finasteride | Finasteride | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | 11 |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | suppressed |
| Carvedilol | Carvedilol | 26 | 13 |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Atenolol | Atenolol | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $567.32 · 31 records | Exact Sciences Corporation | Cologuard Collection Kit, FREESTYLE LIBRE 3, Korlym, MOUNJARO, OtoSight Middle Ear Scope, The Cologuard Plus Collection Kit, VOQUEZNA, Veozah, Wegovy, ZEPBOUND, ZORYVE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error